

APPENDIX

I.



Article

Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission

Diána Martos ¹, Bernadett Tuka ¹, Masaru Tanaka ¹, László Vécsei ^{1,2,*} and Gyula Telegdy ³

¹ MTA-SZTE Neuroscience Research Group, Hungarian Academy of Sciences, University of Szeged (MTA-SZTE), Semmelweis u. 6, H-6725 Szeged, Hungary; martos.diana@med.u-szeged.hu (D.M.); tuka.bernadett@med.u-szeged.hu (B.T.); tanaka.masaru.1@med.u-szeged.hu (M.T.)

² Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary

³ Department of Pathophysiology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 5, H-6725 Szeged, Hungary; telegdy.gyula@med.u-szeged.hu

* Correspondence: vecsei.laszlo@med.u-szeged.hu; Tel.: +36-62-342-361

Abstract: Kynurenic acid (KYNA) is an endogenous tryptophan (Trp) metabolite known to possess neuroprotective property. KYNA plays critical roles in nociception, neurodegeneration, and neuroinflammation. A lower level of KYNA is observed in patients with neurodegenerative diseases such as Alzheimer's and Parkinson's diseases or psychiatric disorders such as depression and autism spectrum disorders, whereas a higher level of KYNA is associated with the pathogenesis of schizophrenia. Little is known about the optimal concentration for neuroprotection and the threshold for neurotoxicity. In this study the effects of KYNA on memory functions were investigated by passive avoidance test in mice. Six different doses of KYNA were administered intracerebroventricularly to previously trained CFLP mice and they were observed for 24 h. High doses of KYNA (i.e., 20–40 µg/2 µL) significantly decreased the avoidance latency, whereas a low dose of KYNA (0.5 µg/2 µL) significantly elevated it compared with controls, suggesting that the low dose of KYNA enhanced memory function. Furthermore, six different receptor blockers were applied to reveal the mechanisms underlying the memory enhancement induced by KYNA. The series of tests revealed the possible involvement of the serotonergic, dopaminergic, α and β adrenergic, and opiate systems in the nootropic effect. This study confirmed that a low dose of KYNA improved a memory component of cognitive domain, which was mediated by, at least in part, four systems of neurotransmission in an animal model of learning and memory.

Keywords: tryptophan; kynurenine; kynurenic acid; passive avoidance; cognitive domain; memory; cognitive enhancer; neurotransmission; receptor blockers; translational



Citation: Martos, D.; Tuka, B.; Tanaka, M.; Vécsei, L.; Telegdy, G. Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission. *Biomedicines* **2022**, *10*, 849. <https://doi.org/10.3390/biomedicines10040849>

Academic Editor: Giuseppe Tringali

Received: 20 March 2022

Accepted: 2 April 2022

Published: 5 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Worldwide, around 50 million people suffer from major neurocognitive disorders. Alzheimer's disease (AD) represents 60–70 percent of cases, imposing a physical, psychological, social, and economic burden on the elderly, their families, caregivers, and society [1]. Patients who develop AD first demonstrate a subtle decline in memory and learning, followed by changes in executive cognitive function and in language and visuospatial processing; indeed, recent evidence suggests that impairments in the ability to process contextual information and in the regulation of responses to threat are related to structural and physiological alterations in the prefrontal cortex (PFC) and medial temporal lobe, addressing how this progressive brain deterioration can eventually cause patterns of cognitive dysfunctions that might be observed in patients with AD [2]. The cause of major neurocognitive disorders remains unknown, but it is considered to be caused by convergence of multifactorial factors including genetic, environmental, infectious, and nutritional components, together with lifestyle, among others [3,4]. There is no remedy for

neurodegenerative diseases. Disease-modifying and symptom-relieving measures are mainstays of treatment. Thus, a tremendous effort has been made to identify pathomechanisms, discover interventional targets, and design novel pharmaceutical agents [5].

KYNA is a metabolite of the Trp-kynurenine (KYN) metabolic system, known to possess a neuroprotective property [6]. The neuroprotective activities are considered to be attributed to the antagonism of the excitatory amino acid receptors (EAARs) such as the N-methyl-D-aspartate (NMDA) receptor, the α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, and the kainic acid receptor [7–10]. Furthermore, KYNA acts as an agonist of the G-protein-coupled receptor 35 (GPR35) and the aryl hydrocarbon receptor (AHR) [11–14]. In addition, opioid receptors are presumed to be interacting partners with KYNA [15,16].

It was previously postulated that the main component of KYNA-induced inhibition in glutamatergic neurotransmission may attribute to noncompetitive inhibition of α 7-nicotinic acetylcholine receptors at glutamatergic presynaptic axon terminals [17], thereby regulating the release of glutamate. However, these results could not be subsequently reproduced by four different and independent groups. Thus, it is still questionable that KYNA may affect glutamate release via the mechanism [18–22]. KYNA plays crucial roles in the regulation of the intracellular Ca^{2+} and mitochondrial dysfunction-induced neuronal cell death in conditions associated with excitotoxicity (Figure 1).




Figure 1. KYNA influences neuronal and glial glutamatergic neurotransmission.

Recently, KYNA and its novel pharmacokinetically favorable analogues demonstrated beneficial effects in animal models of neurologic diseases including pathologic pain sensation, migraine, ischemic stroke, and epilepsy, neurodegenerative diseases, and psychiatric disorder including depression, anxiety, and addiction [23–39]. Accordingly, neuroprotective KYN metabolites, their analogues, the inhibition of Trp-KYN enzymes that are responsible for production of toxic metabolites, their use for biomarkers, and their interaction with adjacent biosystems are under extensive research [40–48].

The beneficial effects were detected when these molecules were peripherally administered in an acute or semichronic manner with relatively high (millimolar) concentrations. Lower levels of KYNA were observed in patients with neurodegenerative diseases and psychiatric disorders [3,6,32,49]. Those illnesses are generally characterized by alterations in inflammatory mediators and mu-opioid receptor, and increased levels in neurotoxic

Try-KYN metabolites, which, furthermore, lead to changes in the amygdala [50]. However, manipulations to elevate KYNA levels have a potential risk of interfering with cognitive functions. Indeed, elevated levels of KYNA in the brain or its chronic application in higher doses are known to evoke cognitive impairment by inhibiting predominantly the glutamatergic system, a phenomenon having been linked to the pathophysiology of AD [51]. Furthermore, prenatal exposure of high levels of KYNA has also been experimentally shown to be associated with sustained cognitive deficits, with implications to schizophrenia [52,53]. Therefore, it is essential to identify the doses of KYNA and KYNA-related molecules to provide neuroprotection without any associated cognitive side effects.

In humans, KYNA is robustly synthesized in the endothelium and its serum levels correlate with homocysteine, a risk factor for cognitive decline; recent studies have suggested that a selective hippocampal increase in the KYNA level may be an important factor contributing to KYNA-related cognitive impairment. Identifying the mechanisms by which high KYNA levels in the hippocampal area may contribute to the deterioration of cognition would provide insight that might be used to manage inflammation-associated mental health disorders, including the discovery of new diagnostic and treatment therapies for depression. Recently, several studies have suggested the effectiveness of noninvasive brain stimulation (NIBS) to interfere and modulate the abnormal activity of neural circuits including the amygdala-mPFC-hippocampus, involved in the acquisition and consolidation of memories, which are altered in psychiatric disorders, such as fear-related disorder, including anxiety disorder, phobias, posttraumatic stress disorder, and depression [54–56].

Our previous studies did not detect any behavior impairment of animals when they were treated intraperitoneally (i.p.) with millimolar doses of KYNA or its analogues [23,57]. The administration of KYNA and its analogues increased inducibility of long-term potentiation (LTP) in the CA1 region in rats, indicating better hippocampal function [58]. However, few data are available on the effects of a low dose KYNA. It was reported that KYNA has a dose-dependent dual action on AMPA receptors; the nanomolar and micromolar concentrations of KYNA could facilitate the responses of AMPA receptors via modulating their desensitization, whereas the millimolar doses of this compound antagonized these receptors [59].

It was demonstrated that KYNA was able to reduce the amplitudes of the field excitatory postsynaptic potentials (EPSPs) in hippocampal slices of young rats at micromolar concentrations, whereas the nanomolar concentrations evoked stimulation. Therefore, KYNA as a 'Janus-faced' molecule may display different effects according to its concentration by acting on different receptors and through mechanisms [60]. A lower endogenous formation of KYNA induces positive effects in cognition. Indeed, the role of the kynurenine aminotransferase II (KAT II), an enzyme responsible for the endogenous KYNA synthesis in the human brain, has been recently emphasized in the mechanisms of memory; activities of KAT I and II showed age-dependent increase with an exception for KAT II in the frontal cortex, which could be related to functional alterations in the PFC reported in psychiatric and brain-damaged patients' memory and learning abilities. Furthermore, recent studies revealed that naturally occurring bilateral lesions in the human ventromedial PFC compromise the capacity of associative learning [61–63], suggesting that PFC dysfunctions cause impairment of aversive learning and emotional memory circuits, which might be transversal across many psychiatric disorders in humans [64]. Pharmacological inhibition or genetic ablation of KAT II reduced KYNA levels in the brain and improved the performance in working/spatial memory and sustained attention tasks in different animal models [65–67]. The inhibition of KAT II, with a subsequent reduction in an endogenous KYNA level, restores normal cognitive function; thus, a manipulation of KYNA levels may be a promising therapeutic target in cognitive impairment associated with elevated concentrations of KYNA in the brain.

2. Materials and Methods

2.1. Experimental Animals and Ethics Statement

All animal experiments complied with the principles of animal care outlined in the instructions of the Ethical Committee for the Protection of Animals in Research of the University of Szeged (Szeged, Hungary), which specifically approved this study (XXIV/352/2012) and the protocol for animal care approved both by the Hungarian Health Committee (40/2013 (II.14.)) and by the European Communities Council Directive (2010/63/EU). C57BL/6J male mice (body weight 25–28 g) were used. The animals were kept and handled during the experiments in accordance with the Regulations of the Faculty of Medicine, University of Szeged, Ethical Committee for the Protection of Animals in Research. Five animals per cage were housed under laboratory conditions with a 12 h dark/12 h light cycle in a temperature-controlled room (24–25 °C) in the Laboratory Animal House of the Department of Neurology in Szeged. Standard mouse chow and tap water were available *ad libitum*.

2.2. Surgery

The mice were anaesthetized with 40% Euthasol (in a dose of 60 mg/kg administered *i.p.*), and a plastic cannula was introduced into the lateral cerebral ventricle and fixed to the skull. The animals were allowed to recover for 5 days. The correct location of the cannula was controlled when dissecting the brain following the completion of the experiments. Only animals with the correct location of the cannula were used in the evaluation of the experiments. All experiments were performed during the morning period.

2.3. Materials

KYNA was purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). The following receptor blockers were applied: cyproheptadine, a nonselective 5-HT₂ serotonergic receptor antagonist, in a dose of 5 mg/kg (Tocris, Bristol, UK); phenoxybenzamine hydrochloride, a nonselective α -adrenergic receptor antagonist, in a dose of 2 mg/kg (Smith Kline and French, Hertz, UK); naloxone, a nonselective opioid receptor antagonist, in a dose of 0.3 mg/kg (Endo Lab Inc., Malvern, PA, USA), haloperidol, a D₂, D₃, D₄ dopamine receptor antagonist, in a dose of 10 μ g/kg (Richter Gedeon Plc., Budapest, Hungary), propranolol hydrochloride, a nonselective β -adrenergic receptor antagonist, in a dose of 2 mg/kg (ICI Ltd., Macclesfield, UK), atropine sulfate, the nonselective muscarinic acetylcholine receptor antagonist in a dose of 2 mg/kg (EGIS, Budapest, Hungary). The effective doses of the receptor antagonists have been determined based on the previous studies published and our previous work. The doses are calibrated in which no change in tested behaviors is observable [68–70]. KYNA was freshly dissolved in 0.9% aqueous saline solution and its pH was set to approximately 7.4 before use. The control animals received only 0.9% saline solution.

2.4. Experimental Groups and Treatments

Animals in the pilot study were divided into 4 groups (1 control and 3 for the different doses of KYNA applied). For the dose-effect examination, 7 groups were examined (1 control and 6 for the different doses of KYNA applied). Animals for further studies were divided into 24 groups (6 control, 6 KYNA, 6 for the different receptor blockers, and 6 combined groups) and the treatments were carried out following the training behavioral test (post-trial) on the second day, as presented in Table 1. KYNA was administered through a polyethylene tube with an external diameter of 1.09 mm (Becton Dickinson PE20) inserted stereotaxically into the right lateral brain ventricle in a volume of 2 μ L *i.c.v.* The different receptor blockers were administered *i.p.* The dose of KYNA was selected based on the results of the dose-effect study (Figure 2); only the most effective dose was used during the different receptor blocker-testing experiments.

Table 1. Protocol of passive avoidance test and treatments.

Groups	1th Day		2nd Day		3rd Day
	Trials	Trial	Post-Trial Treatments		Measure
Control	3 × 2 min	Footshock in the dark part	i.p. saline	30 min later	i.c.v. saline 300 s
KYNA	3 × 2 min	Footshock in the dark part	i.p. saline		i.c.v. KYNA 300 s
Receptor blockers	3 × 2 min	Footshock in the dark part	i.p. receptor blocker		i.c.v. saline 300 s
Combined	3 × 2 min	Footshock in the dark part	i.p. receptor blocker		i.c.v. KYNA 300 s




Figure 2. Dose–response examination of kynurenic acid in mice concerning the passive avoidance latency. * $p < 0.05$, the data in the plots are presented as means \pm SEM. The exact subject numbers per group are indicated in brackets below the corresponding bar in the plots.

2.5. Behavioral Test: Passive Avoidance

The passive avoidance test was performed as previously described in Palotai et al. 2016 [71–74]. On the first day of testing, the mice were placed on an illuminated platform and were allowed to enter the dark compartment for 2 min. Since mice prefer the dark to the light, they normally entered within 5 s. This session was repeated 3 times with all animals, and an additional trial was performed on the following day. However, during this second trial, when the mice entered the dark part of the box, an unavoidable but not harmful mild electric footshock (0.75 mA, 2 s) was given through the grid floor. The gate between the light and dark compartments was closed and the animal could not escape. This learning trial was not repeated, but the mice were immediately removed from the apparatus and treated. The consolidation of passive avoidance behavior was tested 24 h later. Each animal was placed on the light platform and the latency to enter the dark compartment was measured up to a maximum of 300 sec.

2.6. Statistical Analysis

Following the analyses of normality and variance, parametric tests were used in all cases of the receptor blocker measurements, but a nonparametric test was carried out in the KYNA dose–response investigation. The one-way analysis of variance (ANOVA) test was followed by Tukey post hoc test for multiple comparisons with unequal cell size. Kruskal–Wallis rank sum test was followed by pairwise comparisons using Tukey and Kramer (Nemenyi) test with Tukey-Dist approximation for independent samples.

Probability values (p) of less than 0.05 were considered significant. The data in the plots are presented as means \pm SEM. The results (probability values) of treatments as presented in Table 2.

Table 2. The doses and binding affinity of receptor blockers and p -values.

Receptor Blockers (Doses)	Binding Affinity (Ki)	Control vs. Receptor Blocker	Control vs. KYNA	KYNA vs. Receptor Blocker	KYNA vs. Receptor Blocker Combined
Cyproheptadine (5 mg/kg)	1–9 nM [75]	$p < 0.384$	$p < 0.013$	$p < 0.001$	$p < 0.002$
Phenoxybenzamine (2 mg/kg)	108 nM [76]	$p < 0.739$	$p < 0.002$	$p < 0.001$	$p < 0.001$
Naloxone (0.3 mg/kg)	1 nM [77]	$p < 0.814$	$p < 0.022$	$p < 0.004$	$p < 0.006$
Haloperidol (10 μ g/kg)	1.1 nM [78,79]	$p < 0.351$	$p < 0.014$	$p < 0.001$	$p < 0.003$
Propranolol (2 mg/kg)	8.7 nM [80]	$p < 0.711$	$p < 0.043$	$p < 0.003$	$p < 0.046$
Atropine (2 mg/kg)	0.5 nM [81]	$p < 0.998$	$p < 0.030$	$p < 0.041$	$p < 0.092$

3. Results

3.1. Passive Avoidance Tests

3.1.1. Pilot Study

To determine the most preferable effective dose of KYNA in the cognitive processes, 10, 20, and 40 μ g of KYNA dissolved in 2 μ L saline was administered i.c.v. to the mice ($n = 5$ /group). In this preliminary experiment, we observed that 40 μ g of KYNA substantially decreased the avoidance latency, whereas the lower doses did not significantly influence this parameter, as compared with the control animals. These results suggested that the positive cognitive effects of KYNA could be expected when administered in doses lower than 10 μ g (data not shown).

3.1.2. Dose–Effect Examination

Male mice were used ($n = 10$ –27/group) to determine the dose of KYNA that could significantly increase the avoidance latency. We investigated the effect of KYNA in doses of 0.25, 0.5, 1, 2, 4, and 8 μ g in 2 μ L saline. The 0.5 μ g of KYNA prominently elevated the time until the animals entered the shock-associated dark part of the box, as compared with the control group ($p < 0.044$). We concluded that KYNA in a dose of 0.5 μ g improved memory consolidation; therefore, this dose was used for further testing. Higher doses of KYNA were associated with significantly shorter avoidance latency as compared with the 0.5 μ g KYNA-treated group (2 μ g KYNA vs. 0.5 μ g KYNA, $p < 0.013$; 4 μ g KYNA vs. 0.5 μ g KYNA, $p < 0.001$). Other doses did not significantly influence the avoidance behavior of mice (Figure 2).

3.1.3. Examination of Different Receptor Blockers

In all cases, the 0.5 μ g/2 μ L dose of KYNA significantly increased the avoidance latency of mice as compared with the healthy control group in the passive avoidance behavioral test. All groups of the tested receptor blockers were associated with significantly shorter avoidance latency as compared with the 0.5 μ g KYNA-treated group. Furthermore, the groups receiving combined treatments (KYNA plus different receptor blocker compounds) were associated with significantly diminished time spent in the light part of the box, as compared with the group treated with 0.5 μ g of KYNA alone, except for the one receiving

atropine (Table 2, Figure 3). Compared to the control group, the applied receptor blockers did not influence remarkably the avoidance latency (in accordance with that previously reported in [71–74]), whereas the latency values observed in the combination groups did not differ significantly from those observed in the groups treated with the respective receptor blocker alone (Table 2, Figure 3).




Figure 3. Cont.




Figure 3. (a–c) The effects of different receptor blockers and their interaction with KYNA treatment in mice in the passive avoidance test: *Cyproheptadine*, a nonselective 5-HT₂ serotonergic receptor antagonist (a); *phenoxybenzamine*, a nonselective α -adrenergic receptor antagonist (b); *naloxone*, a nonselective opioid receptor antagonist (c); * $p < 0.05$, the data in the plots are presented as means \pm SEM. The exact subject numbers per group are indicated in brackets below the corresponding bar in the plots. (d–f) The effects of different receptor blockers and their interaction with KYNA treatment in mice in the passive avoidance test. *Haloperidol*, a D₂, D₃, D₄ dopamine receptor antagonist (d); *propranolol*, a nonselective β -adrenergic receptor antagonist (e); and *atropine*, a nonselective muscarinic acetylcholine receptor antagonist (f); * $p < 0.05$, the data in the plots are presented as means \pm SEM. The exact subject numbers per group are indicated in brackets below the corresponding bar in the plots.

4. Discussion

Preclinical translational animal studies play a major role in neuroscience research to understand the roles of neuropeptides, neurohormones, and endogenous biomolecules in the normal function of human life such as cognition, emotion, and social interaction, and in pathological alterations developing into neurological and psychiatric disorders [82–97]. Various bioactive molecules are synthesized in the Trp-KYN metabolic system. KYNA is generally described as a neuroprotective molecule, but it is also suspected of being a culprit of cognitive exacerbation in schizophrenia. Thus, the role of KYNA in cognitive function in the brain remains inconclusive [3,48].

This study attempts to determine whether KYNA influences the cognitive function positively in sufficiently low doses, to thus exhibit ‘Janus-faced’ property. The effects of low doses of exogenous KYNA administered by the intracerebroventricular (i.c.v.) route were examined in the passive avoidance cognitive test in mice, with special focus on memory consolidation, retention, and retrieval functions. The possible target(s) and transmitter system(s) involved in the observed effects of KYNA were evaluated by the application of different receptor blockers.

In a previous study, Chiamulera et al. detected that the KYNA treatment did not significantly change the avoidance latency in the passive avoidance tests in mice [98]. On the other hand, Potter et al. observed that the KAT II knockout mice performed better on the passive avoidance behavior test than their wild-type counterparts. The observation was linked to elevated levels of KYNA in the brain and cerebrospinal fluid patients with schizophrenia [67].

Our study confirms that KYNA influences the behavior of mice in the passive avoidance test. While high doses (i.e., 40 $\mu\text{g}/2 \mu\text{L}$) significantly decreased the memory performance of mice, a low dose of 0.5 $\mu\text{g}/2 \mu\text{L}$ significantly enhanced the memory consolidation of mice by increasing in the avoidance latency.

To assess the mechanism of KYNA action in neurotransmission, we apply various receptor antagonists in combination (cyproheptadine for serotonergic neurotransmission; benzamine hydrochloride for α -adrenergic neurotransmission; naloxone for opioid neurotransmission; haloperidol for dopaminergic neurotransmission; propranolol hydrochloride for β -adrenergic neurotransmission; and atropine sulfate for muscarinic acetylcholine neurotransmission). The receptor blockers prevented the action of KYNA on passive avoidance learning, suggesting that the memory enhancement of KYNA is at least involved in serotonergic, adrenergic, dopaminergic, and opiate systems, and implicating an indirect but functionally significant crosstalk between the kynurenine pathway and these systems of neurotransmission in the brain.

The glutamatergic synapse has decisive roles in cognitive brain functions (i.e., learning and memory); the role of NMDA receptors is important for triggering learning-related plasticity, whereas the AMPA receptors are essential for the expression of synaptic changes [58,99,100]. The activation of AMPA receptor-mediated neurotransmission ampakines was proposed as nootropics for mental disability, cognitive disturbances, and memory impairment [101].

Our presumption is that the applied doses of KYNA and its targets have crucial roles in the observed outcome effects. A shift in the balance of the Trp-KYN metabolic system toward the relative excess of neurotoxic molecules such as quinolinic acid (QUIN) has been implicated in the pathomechanisms of several neurological, neurodegenerative and psychiatric disorders, including epilepsy, Huntington’s (HD), Parkinson’s (PD), AD, and depressive disorder. Intervention to restore the balance or KYNA supplementation in the brain has been widely linked to neuroprotective actions in animal models of various diseases [102,103]. However, the influence of the KYN metabolites on certain diseases remains controversial. A potentially protective dose of KYNA may cause cognitive impairment via interfering with physiological NMDA- and AMPA-mediated currents [104,105]. In line with these findings, two concepts emerge regarding the role of an elevated KYNA levels in AD: a pathogenic factor in the development of memory impairment in AD and a

compensatory mechanism against neurotoxicity [106]. Calibrating the equilibrium in the Trp-KYN metabolic system appears to be a complex maneuver.

In healthy subjects, the concentration of KYNA is in the nanomolar and micromolar ranges in the brain and the blood plasma, respectively; however, significant alterations were observed in the concentrations of KYN metabolites in neurodegenerative diseases associated with cognitive impairment [105,107]. Inhibitory effects of peripherally administered L-kynurenine (L-KYN) (single or daily repeated injections) were detected in rats in several behavioral tests; however, these treatments were applied in higher doses (100 and 200 mg/kg i.p.) [108]. These effects may be attributed to the inhibition of ionotropic glutamate receptors, for KYNA blocks both the AMPA and the kainate subtypes, and it has the highest dose-dependent affinity for the strychnine-insensitive glycine-binding site and the glutamate-binding site of NMDA receptors [7,109,110]. The antagonistic action can also induce neuroprotection via the prevention of glutamate excitotoxicity, predominantly through the inhibition of overactivated NMDA receptors localized extrasynaptically [105].

KYNA has dose-dependent dual effects on the AMPA receptors, for it exerts an inhibitory effect in the micromolar concentration range, whereas it evokes facilitation in low nanomolar concentrations [59,60]. The latter effect may be associated with a positive modulatory binding site at the AMPA receptors. The possible molecular mechanisms were detailed recently [111]. It can be hypothesized that the cognitive enhancing effect of KYNA may be attributed to this partial agonism at the AMPA receptors with a sufficient low dose of KYNA. It is suggested that a slight increase in the level of KYNA in the postsynaptic area may exert a preferential inhibition on the extrasynaptic NMDA receptors, thereby being able to protect against excitotoxic neuronal injury, while sparing or (in case of AMPA) even facilitating the physiological synaptic glutamate receptor-mediated currents without interfering with cognitive functions, or possibly even enhancing them (Figure 4).

The effects of cognitive enhancement by KYNA slightly resemble those of memantine, a molecule with a noncompetitive antagonistic low-to-moderate affinity to the NMDA receptors, which thereby has a modest beneficial effect on cognition [112–114]. Our results support that KYNA may have a cognitive enhancer effect when applied in low doses. However, KYNA is barely permeable to the blood–brain barrier (BBB) [115]. The injection procedure applied in our study is far from physiological circumstances, but at present this is the only method available to test the direct effects of KYNA. Our research group has attempted to package KYNA into core-shell nanoparticles to facilitate the penetration of KYNA through the BBB, thereby enhancing the concentration of KYNA in the brain [116]. The high doses of KYNA induced marked ataxia, stereotyped behavior, and muscular hypotonia in a dose-dependent manner. The effects can be alleviated by i.c.v. pretreatment with D-serine, a selective agonist at the strychnine-insensitive glycine binding site of the NMDA receptor complex [117].

L-KYN in combination with probenecid, an organic amino acid transporter inhibitor, improved the spatial memory in animal models of AD and PD [118,119]. The unwanted effects of KYNA and its analogues were tested in several behavioral tests such as spontaneous locomotor activity, working memory performance, and long-lasting, consolidated reference memory; however, the results showed that the higher concentration of KYNA in the brain via the administration of KYNA or its analogue does not cause a perturbation of working memory function or lead to impaired cognitive functions or any significant systemic side effect [23,57,120]. Additionally, an electrophysiological study revealed that one of the KYNA analogues did not decrease but rather increased the potentiation of field EPSPs. It can also be hypothesized that a partial agonistic effect of KYNA or its analogue on glutamate receptors accounts for the paradox effect [58,60]. There are data indicating a relationship between the adrenergic and KYN systems. Indeed, selective beta receptor agonists can increase the cortical endogenous level of KYNA in rat brain slices and mixed glial cultures, an effect that can be blocked by propranolol. This mechanism appears to be mediated by cyclic adenosine monophosphate- and protein kinase A-dependent processes [121].




Figure 4. Hypothetical mechanisms, receptorial and current alterations in normal conditions of glutamatergic neurons and in the presence of KYNA in different dose. A slight increase in the level of KYNA in the postsynaptic area may exert a preferential inhibition on the extrasynaptic NMDA receptors, thereby being able to protect against excitotoxic neuronal injury.

Furthermore, the kynurenines and the dopaminergic systems are in a close relationship, for specific inhibition of KAT II markedly reduces the firing activity of dopaminergic neurons in the ventral tegmental area. The effect is proposed to be specifically carried out by NMDA-receptors and mediated indirectly via a γ -aminobutyric acidergic (GABA) disinhibition [122]. Trp is the common precursor for both serotonin and L-kynurenine. Thus, alteration in the activity of the rate-limiting step of the Trp-KYN metabolic system

influences the serotonin pathway as well. This is suggested in the pathomechanisms of migraine, depression, and certain other psychiatric syndromes [123].

Finally, an indirect interaction may exist between the opioid and the KYN system. The activity of opioid receptor-mediated G-protein activity decreased after chronic systemic treatment with KYNA or its analogue in an animal study [16]. The widespread, complex molecular interactions of KYNA with different receptors may underlie its variable dose-dependent neuromodulatory effects and its significance in the processes of the central nervous system. It would be essential to unveil the effects of low doses of chronically administered KYNA by the systemic route. This would enable the identification the appropriate methods and doses that may be associated with both neuroprotective and cognitive enhancer effects without unwanted adverse effects.

5. Conclusions

Our results suggest that low doses of KYNA can facilitate learning and memory consolidation, as revealed by an experimental cognitive paradigm in healthy mice. Further, investigations are expected to reveal the potentially similar effects of low-dose KYNA in other memory tests, and longitudinal studies with extended follow-up are warranted to determine the effects of chronically administered KYNA in low doses. This approach may represent a potential therapeutic tool in neurodegenerative diseases and chronic conditions with associated cognitive impairments.

Author Contributions: Data collection, D.M. and B.T.; writing—original draft preparation, D.M. and B.T.; writing—review and editing, D.M., B.T. and M.T.; visualization, D.M. and B.T.; supervision, L.V. and G.T.; funding acquisition, L.V. All authors have read and agreed to the published version of the manuscript.

Funding: The current work was supported by National Scientific Research Fund OTKA138125, TUDFO/47138-1/2019-ITM, TKP2020 Thematic Excellence Programme 2020, University of Szeged Open Access Fund (5257).

Institutional Review Board Statement: Ethical Committee for the Protection of Animals in Research of the University of Szeged (Szeged, Hungary), which specifically approved this study (XXIV/352/2012), date of approval: 3 March 2012 and the protocol for animal care approved both by the Hungarian Health Committee (40/2013 (II.14.)) and by the European Communities Council Directive (2010/63/EU).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors are grateful to Ilona Ungi for the invaluable help in the animal experiments.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AD	Alzheimer's disease
AHR	aryl hydrocarbon receptor
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
BBB	blood–brain barrier
EAARs	excitatory amino acid receptors
EPSPs	excitatory postsynaptic potentials
GABA	α -aminobutyric acid
GPR 35	G-protein-coupled receptor 35
HD	Huntington's disease
5-HT ₂	5-hydroxy-triptamin-2 receptor
KYNA	kynurenic acid

KYN	kynurenine
KAT II	kynurenine aminotransferase II enzyme
L-KYN	L-kynurenine
LTP	long-term potentiation
NMDA	N-methyl-D-aspartate receptor
PD	Parkinson's disease
PFC	prefrontal cortex
QUIN	quinolinic acid
Trp	Tryptophan

References

- World Health Organization. Dementia, World Health Organization. 2020. Available online: <https://www.who.int/news-room/fact-sheets/detail/dementia> (accessed on 18 March 2021).
- Battaglia, S.; Garofalo, S.; di Pellegrino, G. Context-dependent extinction of threat memories: Influences of healthy aging. *Sci. Rep.* **2018**, *8*, 12592. [[CrossRef](#)]
- Tanaka, M.; Toldi, J.; Vecsei, L. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. *Int. J. Mol. Sci.* **2020**, *21*, 2431. [[CrossRef](#)] [[PubMed](#)]
- Sini, P.; Dang, T.B.C.; Fais, M.; Galioto, M.; Padedda, B.M.; Lugliè, A.; Iaccarino, C.; Crosio, C. Cyanobacteria, Cyanotoxins, and Neurodegenerative Diseases: Dangerous Liaisons. *Int. J. Mol. Sci.* **2021**, *22*, 8726. [[CrossRef](#)]
- Tanaka, M.; Török, N.; Vecsei, L. Novel Pharmaceutical Approaches in Dementia. In *NeuroPsychopharmacotherapy*; Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C., Eds.; Springer: Cham, Switzerland, 2021. [[CrossRef](#)]
- Encyclopedia. The Tryptophan-Kynurenine Metabolic Pathway. Available online: <https://encyclopedia.pub/8633> (accessed on 15 March 2022).
- Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. *J. Neurochem.* **1989**, *52*, 1319–1328. [[CrossRef](#)]
- Birch, P.J.; Grossman, C.J.; Hayes, A.G. 6,7-Dinitro-quininoxaline-2,3-dione and 6-nitro,7-cyano-quininoxaline-2,3-dione antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor. *Eur. J. Pharmacol.* **1988**, *156*, 177–180. [[CrossRef](#)]
- Perkins, M.N.; Stone, T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. *Brain Res.* **1982**, *247*, 184–187. [[CrossRef](#)]
- Alkondon, M.; Pereira, E.F.; Albuquerque, E.X. Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: Effects of kynurenic acid. *Biochem. Pharmacol.* **2011**, *82*, 842–851. [[CrossRef](#)] [[PubMed](#)]
- Cosi, C.; Mannaioni, G.; Cozzi, A.; Carla, V.; Sili, M.; Cavone, L.; Maratea, D.; Moroni, F. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. *Neuropharmacology* **2011**, *60*, 1227–1231. [[CrossRef](#)] [[PubMed](#)]
- Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. *J. Biol. Chem.* **2006**, *281*, 22021–22028. [[CrossRef](#)] [[PubMed](#)]
- Moroni, F.; Cozzi, A.; Sili, M.; Mannaioni, G. Kynurenic acid: A metabolite with multiple actions and multiple targets in brain and periphery. *J. Neural Transm.* **2012**, *119*, 133–139. [[CrossRef](#)]
- Stone, T.W.; Stoy, N.; Darlington, L.G. An expanding range of targets for kynurenine metabolites of tryptophan. *Trends Pharmacol. Sci.* **2013**, *34*, 136–143. [[CrossRef](#)] [[PubMed](#)]
- Horvath, G.; Kekesi, G.; Tuboly, G.; Benedek, G. Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. *Brain Res.* **2007**, *1155*, 42–48. [[CrossRef](#)]
- Zador, F.; Samavati, R.; Szlavicz, E.; Tuka, B.; Bojnik, E.; Fulop, F.; Toldi, J.; Vecsei, L.; Borsodi, A. Inhibition of opioid receptor mediated G-protein activity after chronic administration of kynurenic acid and its derivative without direct binding to opioid receptors. *CNS Neurol. Dis. Drug Targets* **2014**, *13*, 1520–1529. [[CrossRef](#)] [[PubMed](#)]
- Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implications. *J. Neurosci.* **2001**, *21*, 7463–7473. [[CrossRef](#)] [[PubMed](#)]
- Zadori, D.; Veres, G.; Szalardy, L.; Klivenyi, P.; Fulop, F.; Toldi, J.; Vecsei, L. Inhibitors of the kynurenine pathway as neurotherapeutics: A patent review (2012–2015). *Expert Opin. Ther. Pat.* **2016**, *26*, 815–832. [[CrossRef](#)] [[PubMed](#)]
- Stone, T.W. Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. *Eur. J. Neurosci.* **2007**, *25*, 2656–2665. [[CrossRef](#)] [[PubMed](#)]
- Arnaiz-Cot, J.J.; Gonzalez, J.C.; Sobrado, M.; Baldelli, P.; Carbone, E.; Gandia, L.; Garcia, A.G.; Hernandez-Guijo, J.M. Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. *Eur. J. Neurosci.* **2008**, *27*, 1097–1110. [[CrossRef](#)] [[PubMed](#)]
- Mok, M.H.; Fricker, A.C.; Weil, A.; Kew, J.N. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. *Neuropharmacology* **2009**, *57*, 242–249. [[CrossRef](#)] [[PubMed](#)]

22. Dobelis, P.; Staley, K.J.; Cooper, D.C. Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons. *PLoS ONE* **2012**, *7*, e41108. [[CrossRef](#)] [[PubMed](#)]
23. Nagy, K.; Plangar, I.; Tuka, B.; Gellert, L.; Varga, D.; Demeter, I.; Farkas, T.; Kis, Z.; Marosi, M.; Zadori, D.; et al. Synthesis and biological effects of some kynurenic acid analogs. *Bioorgan. Med. Chem.* **2011**, *19*, 7590–7596. [[CrossRef](#)]
24. Vamos, E.; Pardutz, A.; Varga, H.; Bohar, Z.; Tajti, J.; Fulop, F.; Toldi, J. Vecsei L: L-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. *Neuropharmacology* **2009**, *57*, 425–429. [[CrossRef](#)]
25. Chauvel, V.; Vamos, E.; Pardutz, A.; Vecsei, L.; Schoenen, J.; Multon, S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. *Exp. Neurol.* **2012**, *236*, 207–214. [[CrossRef](#)]
26. Tanaka, M.; Török, N.; Tóth, F.; Szabó, Á.; Vecsei, L. Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway. *Biomedicines* **2021**, *9*, 897. [[CrossRef](#)]
27. Ciapała, K.; Mika, J.; Rojewska, E. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives. *Int. J. Mol. Sci.* **2021**, *22*, 11055. [[CrossRef](#)]
28. Jovanovic, F.; Candido, K.D.; Knezevic, N.N. The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents. *Int. J. Mol. Sci.* **2020**, *21*, 6045. [[CrossRef](#)] [[PubMed](#)]
29. Spekker, E.; Tanaka, M.; Szabó, Á.; Vecsei, L. Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. *Biomedicines* **2021**, *10*, 76. [[CrossRef](#)] [[PubMed](#)]
30. Fila, M.; Chojnacki, J.; Pawlowska, E.; Szczepanska, J.; Chojnacki, C.; Blasiak, J. Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders. *Int. J. Mol. Sci.* **2021**, *22*, 10134. [[CrossRef](#)] [[PubMed](#)]
31. Spekker, E.; Laborc, K.F.; Bohár, Z.; Nagy-Grócz, G.; Fejes-Szabó, A.; Szűcs, M.; Vecsei, L.; Párdutz, Á. Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid. *J. Headache Pain* **2021**, *22*, 17. [[CrossRef](#)]
32. Sas, K.; Robotka, H.; Rozsa, E.; Agoston, M.; Szenasi, G.; Gigler, G.; Marosi, M.; Kis, Z.; Farkas, T.; Vecsei, L.; et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. *Neurobiol. Dis.* **2008**, *32*, 302–308. [[CrossRef](#)] [[PubMed](#)]
33. Gellert, L.; Fuzik, J.; Goblos, A.; Sarkozi, K.; Marosi, M.; Kis, Z.; Farkas, T.; Szatmari, I.; Fulop, F.; Vecsei, L.; et al. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. *Eur. J. Pharmacol.* **2001**, *667*, 182–187. [[CrossRef](#)] [[PubMed](#)]
34. Gellert, L.; Knapp, L.; Nemeth, K.; Heredi, J.; Varga, D.; Olah, G.; Kocsis, K.; Menyhart, A.; Kis, Z.; Farkas, T.; et al. Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion. *Neuroscience* **2013**, *247*, 95–101. [[CrossRef](#)]
35. Demeter, I.; Nagy, K.; Gellert, L.; Vecsei, L.; Fulop, F.; Toldi, J. A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: Special issue related to kynurenine. *J. Neural Transm.* **2012**, *119*, 151–154. [[CrossRef](#)] [[PubMed](#)]
36. Zadori, D.; Nyiri, G.; Szonyi, A.; Szatmari, I.; Fulop, F.; Toldi, J.; Freund, T.F.; Vecsei, L.; Klivenyi, P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. *J. Neural Transm.* **2011**, *118*, 865–875. [[CrossRef](#)] [[PubMed](#)]
37. Hartai, Z.; Klivenyi, P.; Janaky, T.; Penke, B.; Dux, L.; Vecsei, L. Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. *J. Neurol. Sci.* **2005**, *239*, 31–35. [[CrossRef](#)] [[PubMed](#)]
38. Tanaka, M.; Bohár, Z.; Martos, D.; Telegdy, G.; Vecsei, L. Antidepressant-like effects of kynurenic acid in a modified forced swim test. *Pharmacol. Rep.* **2020**, *72*, 449–455. [[CrossRef](#)] [[PubMed](#)]
39. Morales-Puerto, N.; Giménez-Gómez, P.; Pérez-Hernández, M.; Abuin-Martínez, C.; Leticia, G.B.; Vidal, R.; Gutiérrez-López, M.D.; O’Shea, E.; Colado, M.I. Addiction and the kynurenine pathway: A new dancing couple? *Pharmacol. Ther.* **2021**, *223*, 107807. [[CrossRef](#)] [[PubMed](#)]
40. Tanaka, M.; Török, N.; Vecsei, L. Are 5-HT₁ receptor agonists effective anti-migraine drugs? *Expert Opin Pharmacother.* **2021**, *22*, 1221–1225. [[CrossRef](#)] [[PubMed](#)]
41. Erabi, H.; Okada, G.; Shibasaki, C.; Setoyama, D.; Kang, D.; Takamura, M.; Yoshino, A.; Fuchikami, M.; Kurata, A.; Kato, T.A.; et al. Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. *Sci. Rep.* **2020**, *10*, 16822. [[CrossRef](#)]
42. Balogh, L.; Tanaka, M.; Török, N.; Vecsei, L.; Taguchi, S. Crosstalk between Existential Phenomenological Psychotherapy and Neurological Sciences in Mood and Anxiety Disorders. *Biomedicines* **2021**, *9*, 340. [[CrossRef](#)]
43. Hunt, C.; Macedo e Cordeiro, T.; Suchting, R.; de Dios, C.; Cuellar Leal, V.A.; Soares, J.C.; Dantzer, R.; Teixeira, A.L.; Selvaraj, S. Effect of immune activation on the kynurenine pathway and depression symptoms—A systematic review and meta-analysis. *Neurosci. Biobehav. Rev.* **2020**, *118*, 514. [[CrossRef](#)]
44. Carrillo-Mora, P.; Pérez-De la Cruz, V.; Estrada-Cortés, B.; Toussaint-González, P.; Martínez-Cortés, J.A.; Rodríguez-Barragán, M.; Quinzaños-Fresnedo, J.; Rangel-Caballero, F.; Gamboa-Coria, G.; Sánchez-Vázquez, I.; et al. Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. *Neurorehabil. Neural Repair* **2020**, *34*, 936–944. [[CrossRef](#)]

45. Simonato, M.; Dall'Acqua, S.; Zilli, C.; Sut, S.; Tenconi, R.; Gallo, N.; Sfriso, P.; Sartori, L.; Cavallin, F.; Fiocco, U.; et al. Tryptophan Metabolites, Cytokines, and Fatty Acid Binding Protein 2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Biomedicines* **2021**, *9*, 1724. [[CrossRef](#)]
46. Ramírez Ortega, D.; Ugalde Muñiz, P.E.; Blanco Ayala, T.; Vázquez Cervantes, G.I.; Lugo Huitrón, R.; Pineda, B.; González Esquivel, D.F.; Pérez de la Cruz, G.; Pedraza Chaverri, J.; Sánchez Chapul, L.; et al. On the Antioxidant Properties of L-Kynurenine: An Efficient ROS Scavenger and Enhancer of Rat Brain Antioxidant Defense. *Antioxidants* **2022**, *11*, 31. [[CrossRef](#)] [[PubMed](#)]
47. Marrugo-Ramírez, J.; Rodríguez-Núñez, M.; Marco, M.-P.; Mir, M.; Samitier, J. Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease. *Biosensors* **2021**, *11*, 20. [[CrossRef](#)] [[PubMed](#)]
48. Tanaka, M.; Vécsei, L. Monitoring the kynurenine system: Concentrations, ratios or what else? *Adv. Clin. Exp. Med.* **2021**, *30*, 775–778. [[CrossRef](#)] [[PubMed](#)]
49. Török, N.; Tanaka, M.; Vécsei, L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. *Int. J. Mol. Sci.* **2020**, *21*, 9338. [[CrossRef](#)] [[PubMed](#)]
50. Battaglia, S.; Fabius, J.H.; Moravkova, K.; Fracasso, A.; Borgomaneri, S. The Neurobiological Correlates of Gaze Perception in Healthy Individuals and Neurologic Patients. *Biomedicines* **2022**, *10*, 627. [[CrossRef](#)]
51. Baran, H.; Jellinger, K.; Deecke, L. Kynurenine metabolism in Alzheimer's disease. *J. Neural Transm.* **1999**, *106*, 165–181. [[CrossRef](#)] [[PubMed](#)]
52. Pershing, M.L.; Bortz, D.M.; Pocivavsek, A.; Fredericks, P.J.; Jorgensen, C.V.; Vunck, S.A.; Leuner, B.; Schwarcz, R.; Bruno, J.P. Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: Implications for schizophrenia. *Neuropharmacology* **2015**, *90*, 33–41. [[CrossRef](#)] [[PubMed](#)]
53. Pocivavsek, A.; Thomas, M.A.; Elmer, G.I.; Bruno, J.P.; Schwarcz, R. Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. *Psychopharmacology* **2014**, *231*, 2799–2809. [[CrossRef](#)] [[PubMed](#)]
54. Borgomaneri, S.; Battaglia, S.; Sciamanna, G.; Tortora, F.; Laricchiuta, D. Memories are not written in stone: Re-writing fear memories by means of non-invasive brain stimulation and optogenetic manipulations. *Neurosci. Biobehav. Rev.* **2021**, *127*, 334–352. [[CrossRef](#)] [[PubMed](#)]
55. Borgomaneri, S.; Battaglia, S.; Avenanti, A.; Pellegrino, G.D. Don't Hurt Me No More: State-dependent Transcranial Magnetic Stimulation for the treatment of specific phobia. *J. Affect. Disord.* **2021**, *286*, 78–79. [[CrossRef](#)] [[PubMed](#)]
56. Borgomaneri, S.; Battaglia, S.; Garofalo, S.; Tortora, F.; Avenanti, A.; di Pellegrino, G. State-Dependent TMS over Prefrontal Cortex Disrupts Fear-Memory Reconsolidation and Prevents the Return of Fear. *Curr. Biol.* **2020**, *30*, 3672–3679.e4. [[CrossRef](#)]
57. Gellert, L.; Varga, D.; Ruzska, M.; Toldi, J.; Farkas, T.; Szatmari, I.; Fulop, F.; Vecsei, L.; Kis, Z. Behavioural studies with a newly developed neuroprotective KYNA-amide. *J. Neural Transm.* **2012**, *119*, 165–172. [[CrossRef](#)] [[PubMed](#)]
58. Demeter, I.; Nagy, K.; Farkas, T.; Kis, Z.; Kocsis, K.; Knapp, L.; Gellert, L.; Fulop, F.; Vecsei, L.; Toldi, J. Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study. *Neurosci. Lett.* **2013**, *553*, 138–141. [[CrossRef](#)] [[PubMed](#)]
59. Prescott, C.; Weeks, A.M.; Staley, K.J.; Partin, K.M. Kynurenic acid has a dual action on AMPA receptor responses. *Neurosci. Lett.* **2006**, *402*, 108–112. [[CrossRef](#)] [[PubMed](#)]
60. Rozsa, E.; Robotka, H.; Vecsei, L.; Toldi, J. The Janus-face kynurenic acid. *J. Neural Transm.* **2008**, *115*, 1087–1091. [[CrossRef](#)]
61. Battaglia, S.; Harrison, B.J.; Fullana, M.A. Does the human ventromedial prefrontal cortex support fear learning, fear extinction or both? A commentary on subregional contributions. *Mol. Psychiatry* **2021**. [[CrossRef](#)] [[PubMed](#)]
62. Battaglia, S. Neurobiological advances of learned fear in humans. *Adv. Clin. Exp. Med.* **2022**, *31*, 217–221. [[CrossRef](#)] [[PubMed](#)]
63. Garofalo, S.; Timmermann, C.; Battaglia, S.; Maier, M.E.; di Pellegrino, G. Medial Prefrontal Negativity Signals Unexpected Timing of Salient Outcomes. *J. Cogn. Neurosci.* **2017**, *29*, 718–727. [[CrossRef](#)] [[PubMed](#)]
64. Battaglia, S.; Garofalo, S.; di Pellegrino, G.; Starita, F. Revaluing the Role of vmPFC in the Acquisition of Pavlovian Threat Conditioning in Humans. *J. Neurosci.* **2020**, *40*, 8491–8500. [[CrossRef](#)] [[PubMed](#)]
65. Koshy Cherian, A.; Gritton, H.; Johnson, D.E.; Young, D.; Kozak, R.; Sarter, M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. *Neuropharmacology* **2014**, *82*, 41–48. [[CrossRef](#)] [[PubMed](#)]
66. Kozak, R.; Campbell, B.M.; Strick, C.A.; Horner, W.; Hoffmann, W.E.; Kiss, T.; Chapin, D.S.; McGinnis, D.; Abbott, A.L.; Roberts, B.M.; et al. Reduction of brain kynurenic acid improves cognitive function. *J. Neurosci.* **2014**, *34*, 10592–10602. [[CrossRef](#)] [[PubMed](#)]
67. Potter, M.C.; Elmer, G.I.; Bergeron, R.; Albuquerque, E.X.; Guidetti, P.; Wu, H.Q.; Schwarcz, R. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. *Neuropsychopharmacology* **2010**, *35*, 1734–1742. [[CrossRef](#)] [[PubMed](#)]
68. Tanaka, M.; Schally, A.V.; Telegdy, G. Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71. *Behav. Brain Res.* **2012**, *228*, 388–391. [[CrossRef](#)] [[PubMed](#)]
69. Telegdy, G.; Schally, A.V. Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. *Behav. Brain Res.* **2012**, *233*, 326–330. [[CrossRef](#)] [[PubMed](#)]
70. Telegdy, G.; Tiricz, H.; Adamik, A. Involvement of neurotransmitters in urocortin-induced passive avoidance learning in mice. *Behav. Brain Bull.* **2005**, *67*, 242–247. [[CrossRef](#)] [[PubMed](#)]

71. Palotai, M.; Telegdy, G.; Bagosi, Z.; Jaszberenyi, M. The action of neuropeptide AF on passive avoidance learning. Involvement of neurotransmitters. *Neurobiol. Learn Mem.* **2016**, *127*, 34–41. [[CrossRef](#)] [[PubMed](#)]
72. Palotai, M.; Telegdy, G.; Tanaka, M.; Bagosi, Z.; Jászberényi, M. Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice. *Behav. Brain Res.* **2014**, *274*, 264–269. [[CrossRef](#)]
73. Telegdy, G.; Tanaka, M.; Schally, A.V. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. *Behav. Brain Res.* **2011**, *224*, 155–158. [[CrossRef](#)]
74. Telegdy, G.; Adamik, A.; Tanaka, M.; Schally, A.V. Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats. *Regul. Pept.* **2010**, *159*, 142–147. [[CrossRef](#)] [[PubMed](#)]
75. Petroianu, G.A. Hyperthermia and Serotonin: The Quest for a “Better Cyproheptadine”. *Int. J. Mol. Sci.* **2022**, *23*, 3365. [[CrossRef](#)] [[PubMed](#)]
76. Regan, J.W.; DeMarinis, R.M.; Caron, M.G.; Lefkowitz, R.J. Identification of the subunit-binding site of alpha 2-adrenergic receptors using [3H]phenoxybenzamine. *J. Biol. Chem.* **1984**, *259*, 7864–7869. [[CrossRef](#)]
77. National Center for Biotechnology Information. PubChem Bioassay Record for Bioactivity AID 1135637—SID 103170037, Bioactivity for AID 1135637—SID 103170037, Source: ChEMBL. Available online: <https://pubchem.ncbi.nlm.nih.gov/bioassay/1135637#sid=103170037> (accessed on 25 March 2022).
78. National Center for Biotechnology Information. PubChem Bioassay Record for Bioactivity AID 65111—SID 103167216, Bioactivity for AID 65111—SID 103167216, Source: ChEMBL. Available online: <https://pubchem.ncbi.nlm.nih.gov/bioassay/65111#sid=103167216> (accessed on 25 March 2022).
79. Fan, L.; Tan, L.; Chen, Z.; Qi, J.; Nie, F.; Luo, Z.; Cheng, J.; Wang, S. Haloperidol bound D₂ dopamine receptor structure inspired the discovery of subtype selective ligands. *Nat. Commun.* **2020**, *11*, 1074. [[CrossRef](#)] [[PubMed](#)]
80. National Center for Biotechnology Information. PubChem Bioassay Record for Bioactivity AID 42040—SID 103164951, Bioactivity for AID 42040—SID 103164951, Source: ChEMBL. Available online: <https://pubchem.ncbi.nlm.nih.gov/bioassay/42040#sid=103164951> (accessed on 25 March 2022).
81. Xu, J.; Chuang, D.M. Muscarinic acetylcholine receptor-mediated phosphoinositide turnover in cultured cerebellar granule cells: Desensitization by receptor agonists. *J. Pharmacol. Exp. Ther.* **1987**, *242*, 238–244.
82. Tanaka, M.; Telegdy, G. Neurotransmissions of antidepressant-like effects of neuromedin U-23 in mice. *Behav. Brain Res.* **2014**, *259*, 196–199. [[CrossRef](#)] [[PubMed](#)]
83. Thabault, M.; Turpin, V.; Maisterrena, A.; Jaber, M.; Egloff, M.; Galvan, L. Cerebellar and Striatal Implications in Autism Spectrum Disorders: From Clinical Observations to Animal Models. *Int. J. Mol. Sci.* **2022**, *23*, 2294. [[CrossRef](#)] [[PubMed](#)]
84. Tanaka, M.; Csabafi, K.; Telegdy, G. Neurotransmissions of antidepressant-like effects of kisspeptin-13. *Regul. Pept.* **2013**, *180*, 1–4. [[CrossRef](#)]
85. Correia, B.S.B.; Nani, J.V.; Waladares Ricardo, R.; Stanisic, D.; Costa, T.B.B.C.; Hayashi, M.A.F.; Tasic, L. Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia. *Biomedicines* **2021**, *9*, 235. [[CrossRef](#)]
86. Swingler, T.E.; Niu, L.; Pontifex, M.G.; Vauzour, D.; Clark, I.M. The microRNA-455 Null Mouse Has Memory Deficit and Increased Anxiety, Targeting Key Genes Involved in Alzheimer’s Disease. *Int. J. Mol. Sci.* **2022**, *23*, 554. [[CrossRef](#)] [[PubMed](#)]
87. Tanaka, M.; Kádár, K.; Tóth, G.; Telegdy, G. Antidepressant-like effects of urocortin 3 fragments. *Brain Res. Bull.* **2011**, *84*, 414–418. [[CrossRef](#)] [[PubMed](#)]
88. Giménez-Llort, L.; Marin-Pardo, D.; Marazuela, P.; Hernández-Guillamón, M. Survival Bias and Crosstalk between Chronological and Behavioral Age: Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging. *Biomedicines* **2021**, *9*, 636. [[CrossRef](#)]
89. Muntsant, A.; Giménez-Llort, L. Genotype Load Modulates Amyloid Burden and Anxiety-like Patterns in Male 3xTg-AD Survivors despite Similar Neuro-Immunoendocrine, Synaptic and Cognitive Impairments. *Biomedicines* **2021**, *9*, 715. [[CrossRef](#)]
90. Santana-Santana, M.; Bayascas, J.-R.; Giménez-Llort, L. Fine-Tuning the PI3K/Akt Signaling Pathway Intensity by Sex and Genotype-Load: Sex-Dependent Homozygotic Threshold for Somatic Growth but Feminization of Anxious Phenotype in Middle-Aged PDK1 K465E Knock-In and Heterozygous Mice. *Biomedicines* **2021**, *9*, 747. [[CrossRef](#)]
91. Vila-Merkle, H.; González-Martínez, A.; Campos-Jiménez, R.; Martínez-Ricós, J.; Teruel-Martí, V.; Blasco-Serra, A.; Lloret, A.; Celada, P.; Cervera-Ferri, A. The Oscillatory Profile Induced by the Anxiogenic Drug FG-7142 in the Amygdala–Hippocampal Network Is Reversed by Infralimbic Deep Brain Stimulation: Relevance for Mood Disorders. *Biomedicines* **2021**, *9*, 783. [[CrossRef](#)]
92. Smagin, D.A.; Kovalenko, I.L.; Galyamina, A.G.; Belozertseva, I.V.; Tamkovich, N.V.; Baranov, K.O.; Kudryavtseva, N.N. Chronic Lithium Treatment Affects Anxious Behaviors and the Expression of Serotonergic Genes in Midbrain Raphe Nuclei of Defeated Male Mice. *Biomedicines* **2021**, *9*, 1293. [[CrossRef](#)]
93. Lee, E.C.; Hong, D.-Y.; Lee, D.-H.; Park, S.-W.; Lee, J.Y.; Jeong, J.H.; Kim, E.-Y.; Chung, H.-M.; Hong, K.-S.; Park, S.-P.; et al. Inflammation and Rho-Associated Protein Kinase-Induced Brain Changes in Vascular Dementia. *Biomedicines* **2022**, *10*, 446. [[CrossRef](#)] [[PubMed](#)]
94. Castillo-Mariquero, L.; Pérez-García, M.J.; Giménez-Llort, L. Modeling Functional Limitations, Gait Impairments, and Muscle Pathology in Alzheimer’s Disease: Studies in the 3xTg-AD Mice. *Biomedicines* **2021**, *9*, 1365. [[CrossRef](#)] [[PubMed](#)]
95. Lamoine, S.; Cumenal, M.; Barriere, D.A.; Pereira, V.; Fereyrolles, M.; Prival, L.; Barbier, J.; Boudieu, L.; Brassat, E.; Bertin, B.; et al. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. *Int. J. Mol. Sci.* **2022**, *23*, 98. [[CrossRef](#)]

96. Quirant-Sánchez, B.; Mansilla, M.J.; Navarro-Barriuso, J.; Presas-Rodríguez, S.; Teniente-Serra, A.; Fondelli, F.; Ramo-Tello, C.; Martínez-Cáceres, E. Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon- β in a Preclinical Model of Multiple Sclerosis. *Biomedicines* **2021**, *9*, 1758. [[CrossRef](#)]
97. Jeong, W.-H.; Kim, W.-I.; Lee, J.-W.; Park, H.-K.; Song, M.-K.; Choi, I.-S.; Han, J.-Y. Modulation of Long-Term Potentiation by Gamma Frequency Transcranial Alternating Current Stimulation in Transgenic Mouse Models of Alzheimer's Disease. *Brain Sci.* **2021**, *11*, 1532. [[CrossRef](#)] [[PubMed](#)]
98. Chiamulera, C.; Costa, S.; Reggiani, A. Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. *Psychopharmacology* **1990**, *102*, 551–552. [[CrossRef](#)] [[PubMed](#)]
99. Tocco, G.; Maren, S.; Shors, T.J.; Baudry, M.; Thompson, R.F. Long-term potentiation is associated with increased [3H]AMPA binding in rat hippocampus. *Brain Res.* **1992**, *573*, 228–234. [[CrossRef](#)]
100. Williams, J.M.; Guevremont, D.; Mason-Parker, S.E.; Luxmanan, C.; Tate, W.P.; Abraham, W.C. Differential trafficking of AMPA and NMDA receptors during long-term potentiation in awake adult animals. *J. Neurosci.* **2007**, *27*, 14171–14178. [[CrossRef](#)] [[PubMed](#)]
101. Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.M.; Bartolini, A.; Manetti, D.; Romanelli, M.N.; Gualtieri, F. AMPA-receptor activation is involved in the anti-amnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2003**, *368*, 538–545. [[CrossRef](#)] [[PubMed](#)]
102. Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenic acid in the CNS: Recent advances and new questions. *Nat. Rev. Drug Discov.* **2013**, *12*, 64–82. [[CrossRef](#)] [[PubMed](#)]
103. Ostapiuk, A.; Urbanska, E.M. Kynurenic acid in neurodegenerative disorders—unique neuroprotection or double-edged sword? *CNS Neurosci. Ther.* **2022**, *28*, 19–35. [[CrossRef](#)] [[PubMed](#)]
104. Tanaka, M.; Bohár, Z.; Vecsei, L. Are Kynurenic Acid Accomplices or Principal Villains in Dementia? Maintenance of Kynurenic Acid Metabolism. *Molecules* **2020**, *25*, 564. [[CrossRef](#)] [[PubMed](#)]
105. Szalardy, L.; Zadori, D.; Toldi, J.; Fulop, F.; Klivenyi, P.; Vecsei, L. Manipulating kynurenic acid levels in the brain—On the edge between neuroprotection and cognitive dysfunction. *Curr. Top. Med. Chem.* **2012**, *12*, 1797–1806. [[CrossRef](#)]
106. Dezsi, L.; Tuka, B.; Martos, D.; Vecsei, L. Alzheimer's disease, astrocytes and kynurenic acid. *Cur. Alzheimer Res.* **2015**, *12*, 462–480. [[CrossRef](#)] [[PubMed](#)]
107. Vecsei, L. (Ed.) *Kynurenic acid in the Brain: From Experiments to Clinics*; Nova Science Publishers Inc.: New York, NY, USA, 2005; Available online: <https://www.abebooks.com/9781594543654/Kynurenic-acid-in-the-Brain-Experiments-to-Clinics-Vecsei-1594543658/plp> (accessed on 18 March 2022).
108. Vecsei, L.; Beal, M.F. Influence of kynurenic acid treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. *Pharmacol. Biochem. Behav.* **1990**, *37*, 71–76. [[CrossRef](#)]
109. Swartz, K.J.; During, M.J.; Freese, A.; Beal, M.F. Cerebral synthesis and release of kynurenic acid: An endogenous antagonist of excitatory amino acid receptors. *J. Neurosci.* **1990**, *10*, 2965–2973. [[CrossRef](#)] [[PubMed](#)]
110. Birch, P.J.; Grossman, C.J.; Hayes, A.G. Kynurenic acid antagonizes responses to NMDA via an action at the strychnine-insensitive glycine receptor. *Eur. J. Pharmacol.* **1988**, *154*, 85–87. [[CrossRef](#)]
111. Csapo, E.; Majlath, Z.; Juhasz, A.; Roos, B.; Hetenyi, A.; Toth, G.K.; Tajti, J.; Vecsei, L.; Dekany, I. Determination of binding capacity and adsorption enthalpy between Human Glutamate Receptor (GluR1) peptide fragments and kynurenic acid by surface plasmon resonance experiments. *Colloids and Surfaces B. Biointerfaces* **2014**, *123*, 924–929. [[CrossRef](#)] [[PubMed](#)]
112. Wilkinson, D. A review of the effects of memantine on clinical progression in Alzheimer's disease. *Int. J. Geriatr. Psychiatry* **2012**, *27*, 769–776. [[CrossRef](#)] [[PubMed](#)]
113. Herrmann, N.; Li, A.; Lanctot, K. Memantine in dementia: A review of the current evidence. *Expert Opin. Pharmacother.* **2011**, *12*, 787–800. [[CrossRef](#)]
114. Majlath, Z.; Torok, N.; Toldi, J.; Vecsei, L. Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. *Curr. Neuropharmacol.* **2016**, *14*, 200–209. [[CrossRef](#)] [[PubMed](#)]
115. Fukui, S.; Schwarcz, R.; Rapoport, S.I.; Takada, Y.; Smith, Q.R. Blood-brain barrier transport of kynurenic acid: Implications for brain synthesis and metabolism. *J. Neurochem.* **1991**, *56*, 2007–2017. [[CrossRef](#)] [[PubMed](#)]
116. Varga, N.; Csapo, E.; Majlath, Z.; Ilisz, I.; Krizbai, I.A.; Wilhelm, I.; Knapp, L.; Toldi, J.; Vecsei, L.; Dekany, I. Targeting of the kynurenic acid across the blood-brain barrier by core-shell nanoparticles. *Eur. J. Pharm. Sci.* **2016**, *86*, 67–74. [[CrossRef](#)]
117. Vecsei, L.; Beal, M.F. Intracerebroventricular injection of kynurenic acid, but not kynurenic acid, induces ataxia and stereotyped behavior in rats. *Brain Res. Bull.* **1990**, *25*, 623–627. [[CrossRef](#)]
118. Carrillo-Mora, P.; Mendez-Cuesta, L.A.; Perez-De La Cruz, V.; Fortoul-van Der Goes, T.I.; Santamaria, A. Protective effect of systemic L-kynurenic acid and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25–35) in rat hippocampus. *Behav. Brain Res.* **2010**, *210*, 240–250. [[CrossRef](#)] [[PubMed](#)]
119. Silva-Adaya, D.; Perez-De La Cruz, V.; Villeda-Hernandez, J.; Carrillo-Mora, P.; Gonzalez-Herrera, I.G.; Garcia, E.; Colin-Barenque, L.; Pedraza-Chaverri, J.; Santamaria, A. Protective effect of L-kynurenic acid and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenic acid as a protective strategy. *Neurotoxicol. Teratol.* **2011**, *33*, 303–312. [[CrossRef](#)] [[PubMed](#)]

120. Justinova, Z.; Mascia, P.; Wu, H.Q.; Secci, M.E.; Redhi, G.H.; Panlilio, L.V.; Scherma, M.; Barnes, C.; Parashos, A.; Zara, T.; et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. *Nat. Neurosci.* **2013**, *16*, 1652–1661. [[CrossRef](#)]
121. Luchowska, E.; Kloc, R.; Olajosy, B.; Wnuk, S.; Wielosz, M.; Owe-Larsson, B.; Urbanska, E.M. beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2009**, *33*, 519–529. [[CrossRef](#)] [[PubMed](#)]
122. Linderholm, K.R.; Alm, M.T.; Larsson, M.K.; Olsson, S.K.; Goiny, M.; Hajos, M.; Erhardt, S.; Engberg, G. Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons. *Neuropharmacology* **2016**, *102*, 42–47. [[CrossRef](#)] [[PubMed](#)]
123. Tajti, J.; Csati, A.; Vecsei, L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. *Expert Opin. Drug Metab. Toxicol.* **2014**, *10*, 1509–1520. [[CrossRef](#)]

III.



Antidepressant-like effects of kynurenic acid in a modified forced swim test

Masaru Tanaka^{1,2} · Zsuzsanna Bohár^{1,2} · Diána Martos² · Gyula Telegdy^{1,3} · László Vécsei^{1,2}

Received: 16 July 2019 / Revised: 26 November 2019 / Accepted: 3 December 2019
© The Author(s) 2020

Abstract

Background Kynurenic acid (KYNA) is an L-tryptophan metabolite with neuromodulatory activities, regulating the release of neurotransmitters such as glutamate, dopamine (DA), and acetylcholine (Ach). Dysregulation of the kynurenine pathway has been associated with neurodegenerative, neurological, and psychological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, major depressive disorder, and schizophrenia.

Methods The antidepressant-like effects of KYNA were studied with a modified mouse forced swimming test (FST), and the potential involvement of the serotonin (SER), norepinephrine, DA, Ach, *N*-methyl-D-aspartate, or gamma-aminobutyric acid subunit A (GABA_A) receptors in its antidepressant-like effect was assayed by modified combination mouse FST. In combination studies, the mice were pretreated with the respective receptor antagonist, cyproheptadine (CPH), phenoxybenzamine, yohimbine, propranolol, haloperidol (HPD), atropine, MK-801, or bicuculline (BCL).

Results The FST revealed that KYNA reversed immobility, climbing, and swimming times, suggesting the antidepressant-like effects of KYNA. Furthermore, the combination studies showed that CPH prevented the antidepressant-like effects of KYNA on immobility, climbing, and swimming times, whereas HPD reduced climbing time and BCL influenced immobility and climbing times and prevented the effects of KYNA on swimming time.

Conclusions The results demonstrated, for the first time, the presence of antidepressant-like effects of KYNA in a modified mouse FST. Furthermore, modified combination FST showed that the antidepressant-like actions of KYNA strongly interacted with 5-hydroxytryptamine type 2 SER-ergic receptors, weakly interacted with D₂, D₃, D₄ DA-ergic receptors, and interacted moderately with GABA_A receptors.

Keywords Tryptophan · Kynurenine · Kynurenic acid · Antidepressants · Neurotransmitter receptors · Depression

Introduction

Major depressive disorder (MDD) has been linked to imbalances of central nervous system (CNS) neurotransmitters such as serotonin (SER), norepinephrine (NE), dopamine (DA), acetylcholine (Ach), glutamate (Glu), and gamma (γ)-aminobutyric acid (GABA). Tryptophan

(TRP) metabolism has been observed to play a role in the pathophysiology of MDD. 1-month treatment with a low TRP diet significantly increased the immobility time in the forced swim test (FST) in rats, suggesting the induction of depression-like behavior. Meanwhile, TRP depletion studies showed exacerbated mood symptoms in remittantly depressed patients, familiarly risk patients, and patients on anti-depressant drugs. Furthermore, supplements containing TRP have been reported to improve mood symptoms in MDD [1].

Kynurenic acid (KYNA) is a metabolite in the kynurenine (KYN) pathway from the essential amino acid L-TRP, which is also a precursor of SER and melatonin in the melatonin pathway [2]. KYNA is a noncompetitive antagonist at the glycine site B of the *N*-methyl-D-aspartate (NMDA) Glu receptor, while quinolinic acid (QUIN) is an endogenous agonist at the NMDA receptor. Thus,

✉ Masaru Tanaka
tanaka.masaru.1@med.u-szeged.hu

¹ MTA-SZTE, Neuroscience Research Group, Szeged, Hungary

² Department of Neurology, Interdisciplinary Excellence Centre, Faculty of Medicine, Albert Szent-Györgyi Health Centre, University of Szeged, Szeged, Hungary

³ Department of Pathophysiology, Faculty of Medicine, University of Szeged, Szeged, Hungary

the KYN pathway products, KYNA, and QUIN mutually influence neurotoxicity, excitotoxicity, cytotoxicity, and peroxidative actions at the NMDA receptor [3] (Fig. 1).

In this study, antidepressant-like effects of KYNA were studied and the potential involvement of the SER, NE, DA, Ach, NMDA, and GABA receptors in its antidepressant-like effect was investigated in a modified FST in mice. The mice were pretreated with a nonselective 5-hydroxytryptamine (5-HT)₂ SER-ergic receptor antagonist, cyproheptadine (CPH), a nonselective alpha (α)-adrenergic receptor (ADR) antagonist, phenoxybenzamine (PHB), an alpha-2 (α 2)-ADR antagonist, yohimbine (YHB), a beta (β)-ADR antagonist, propranolol (PPL), a D₂, D₃, D₄ DA receptor antagonist, haloperidol (HPD), a nonselective muscarinic Ach receptor antagonist, atropine (ATR), a noncompetitive NMDA receptor

antagonist, MK-801 or a GABA subunit A (GABA_A) receptor antagonist, bicuculline (BCL).

Materials and methods

Animals and ethical approval

CD₁ (Charles Dawley) male mice, generally employed as animal models in depression and kynurenine research, were kept and handled during the experiments in accordance with the guidelines of the 8th Edition of the Guide for the Care and Use of Laboratory Animals and the Use of Animals in Research of the International Association for the Study of Pain and the directive of the European Economic Community (86/609/ECC). The experiments




Fig. 1 The kynurenine pathway. More than 95% of TRP is metabolized in the KYN pathway except for protein synthesis. More than 95% of TRP is converted by the hepatic rate-limiting TDO and the rest of TRP, by ubiquitous rate-limiting IDO1 and IDO2 to KYN. Cortisol induces TDO, while α -IFN, γ -INF, and α -TNF induce IDO1. L-KYN is converted to AA, 3-HK, and KYNA. KYNA is an antagonist at NMDA receptor. AA and 3-HK are converted to 3-OHAA and further to QUIN. 3-HK and QUIN are agonists at NMDA receptor.

QUIN is converted to NAD⁺, which is a feedback inhibitor of TDO. TRP, tryptophan; SER, serotonin; TDO, tryptophan 2,3-dioxygenase; IDO, indoleamine 2,3-oxygenase; IFN, interferon; TNF, tumor necrosis factor; KYN, kynurenine; KYNA, kynurenic acid; AA, anthranilic acid; 3-HK, 3-hydroxykynurenine; NMDA, *N*-methyl-D-aspartate; 3-OHAA, 3-hydroxyanthranilic acid; QUIN, quinolinic acid; NAD⁺, nicotinamide adenine dinucleotide

were approved by the Committee of Animal Research at the University of Szeged (I.74-24/2018) and the Scientific Ethics Committee for Animal Research of the Protection of Animals Advisory Board (XI./240/2019). Each animal was used only once in the experiments. The animals were about 6 weeks old and weighed between 28 and 35 g. They were housed under standard laboratory conditions at constant temperature (25 ± 1 °C) and on a 12-h dark–light cycle (lights on at 06:00–18:00 h) with free access to tap water and standard laboratory food. At least 1 week of recovery post-surgery was allowed before the experiments. The suffering of the animals and the number of animals used were kept to a minimum.

Surgery

To allow intracerebroventricular (*icv*) administration, a polystyrene cannula was implanted into the right lateral brain ventricle of each mouse at the coordinates 0.2 mm posterior, 0.2 mm lateral to the bregma, and 2.0 mm deep from the dural surface [4]. The cannula was fixed with cyanoacrylate (Ferrobond) (Budapest, Hungary). The *icv* administration was performed 5 days after the surgery.

Materials

KYNA was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). CPH hydrochloride from Tocris (Bristol, UK); PHB hydrochloride from Smith Kline & French (Herts, UK); YHB hydrochloride from Tocris (Cologne, Germany); PPL hydrochloride from ICI Ltd. (Macclesfield, UK); ATR sulfate from EGIS (Budapest, Hungary); HPD from G. Richter (Budapest, Hungary); MK-801 from Sigma-Aldrich Corporation (St. Louis, MO, USA) and BCL methiodide from Sandoz (Basel, Switzerland). KYNA was dissolved in sterile pyrogen-free 0.9% saline and administered *icv* via the cannula in a volume of 2 μ l. Physiological saline (0.9% NaCl) was used as a control.

Forced swimming test

The modified mouse FST was performed as reported previously [5]. The mice were placed individually in a glass cylinder of 12 cm in diameter and 30 cm in height. Water (25 ± 1 °C) was filled to a height of 20 cm. Fresh water was used for each mouse. A 15-min pretest was carried out 24 h before the 3-min test session. 30 min prior to the test session, KYNA was administered *icv* at a volume of 2 μ l, at doses of 0.1 mM, 0.5 mM, 1.0 mM, 1.5 mM or 2.0 mM.

In the modified combination FST, 30 min prior to KYNA (2.0 mM *icv*) administration, the following receptor blockers were administered intraperitoneally (*ip*): CPH (3 mg/kg *ip*) ($N=15$), PHB (2 mg/kg *ip*) ($N=15$), YHB (5 mg/kg *ip*) ($N=10$), PPL (5 mg/kg *ip*) ($N=10$), HPD (10 μ g/kg *ip*) ($N=15$), ATR (2 mg/kg *ip*) ($N=15$), MK-801 (2 mg/kg *ip*) ($N=10$) or, BCL (2 mg/kg *ip*) ($N=10$). Physiological saline was used for the control. A time-sampling technique was conducted to count the duration of climbing, swimming, and immobility times.

Open field test

Locomotor activity was assayed by the open field test. The mice were placed individually in the center of a 35 cm \times 35 cm open-field box consisting of 49 squares. KYNA (2.0 mM *icv*) was administered 30 min before the exploratory test session, which lasted 3 min. The total number of floor units entered, the number of occasions on which the animals stood on their hind legs and the number of occurrences of face washing, forepaw licking and head stroking, each of which indicated the ambulatory activity, the total number of rearing and the grooming frequency were monitored.

Statistical analysis

The analysis of variance (two-way ANOVA) test was followed by Tukey's test for multiple comparisons with unequal cell size. Probability values (p) of less than 0.05 were regarded as indicative of significant differences.

Results

Compared to controls, a dose of 1.0 mM KYNA significantly decreased immobility time [$F(3,35) = 10.68, p < 0.05$]. 1.5 mM significantly decreased immobility time [$F(3,35) = 13.93, p < 0.05$] and significantly increased swimming time [$F(3,35) = 6.73, p < 0.05$]. 2.0 mM significantly decreased immobility time [$F(3,35) = 14.98, p < 0.05$], significantly increased climbing time [$F(3,35) = 7.75, p < 0.05$], and significantly increased swimming time [$F(3,35) = 11.10, p < 0.05$]. The results suggest that KYNA induces antidepressant-like effects with doses of 1.0 mM, 1.5 mM, and 2.0 mM (Fig. 2).

Pretreatment with CPH significantly increased immobility time and significantly decreased swimming time compared to KYNA. It suggests the possible involvement of the SER receptor in KYNA-induced antidepressant-like effects. Pretreatment with PHB did not reverse immobility, climbing, or swimming times compared to KYNA, thus the NE receptor may not be involved in KYNA-induced antidepressant-like




Fig. 2 The effect of kynurenic acid (KYNA) on immobility, climbing, and swimming times in a modified mouse forced swim test (FST). Compared to controls, KYNA significantly decreased immobility time in doses higher than 1.0 mM; significantly increased climbing time in a dose of 2.0 mM; significantly increased swimming time in doses of higher than 1.5 mM. Thus, KYNA showed the antidepressant-like effects in a modified mouse FST. Control ($N=12$), KYNA 0.1 mM *icv* ($N=12$), KYNA 0.5 mM *icv* ($N=12$), KYNA 1.0 mM *icv* ($N=12$), KYNA 1.5 mM *icv* ($N=12$), KYNA 2.0 mM *icv* ($N=12$). \times , $p < 0.05$ vs. control (N , the number of animals; p , probability)

effects. Likewise, pretreatment with YHB did not reverse immobility, climbing, and swimming times compared to KYNA, so the α 2-ADR receptor also may not be involved in KYNA-induced antidepressant-like effects nor did pretreatment with PPL reverse climbing, swimming, and immobility times compared to KYNA, so the β -ADR receptor is not involved in KYNA-induced antidepressant-like effects. Pretreatment with HPD did not change the immobility or

swimming times but did decrease climbing time compared to KYNA. It suggests a minimal involvement of the D_2 , D_3 , D_4 DA receptor in KYNA-induced antidepressant-like effects.

Pretreatment with ATR did not affect immobility, climbing, or swimming times compared to KYNA, so the muscarinic Ach receptor may not be involved in KYNA-induced antidepressant-like effects. Likewise, pretreatment with MK-801 did not affect climbing, swimming or immobility times compared to KYNA, thus the NMDA receptor may not be involved in KYNA-induced antidepressant-like effects. Pretreatment with BCL increased immobility time, decreased climbing time, and significantly decreased swimming time compared to KYNA, suggesting a possible involvement of the $GABA_A$ receptor in KYNA-induced antidepressant-like effects (Fig. 3).

No significant alterations in locomotive, rearing or grooming activities were observed following the *icv* administration of 2.0 mM KYNA (data not shown).

The above results revealed the presence of antidepressant-like effects of KYNA in a modified mouse FST, and the antidepressant-like actions of KYNA strongly interacted with $5-HT_2$ SER-ergic receptors, weakly interacted with D_2 , D_3 , D_4 DA-ergic receptors, and moderately interacted with $GABA_A$ receptors (Table 1).

Discussion

Disruption of the KYN pathway has been implicated in the pathophysiology of MDD [6]. The relationship between plasma KYN concentration and anxiety and depression in psychiatric patients has been studied. Plasma KYN concentration was increased in endogenous anxiety and decreased in endogenous depression. It was also observed that KYN, QUIN, and 3-hydroxy-KYN (3-HK) had anxiogenic effects, while KYNA was anxiolytic for mice in a dark–light chamber. Accordingly, it has been suggested that a group of KYN metabolites and neurokynurenes (NEKYs) are participants in depression [6, 7].

The SER hypothesis postulates that a deficit of SER in the CNS is the cause of MDD. TRP is the sole precursor of peripherally and centrally produced SER, and approximately 95 to 99% of dietary TRP not used in protein synthesis is metabolized in the KYN pathway. Thus, a small portion of TRP is available for SER-melatonin synthesis. Furthermore, it was proposed that SER deficiency in MDD was caused by a shunt of TRP metabolism from the formation of SER towards the production of KYN due to the activation of the hepatic rate-limiting enzyme, TRP 2,3-dioxygenase (TDO), which is activated by the primary stress hormone, cortisol. Activation of the ubiquitous rate-limiting enzyme, indoleamine 2, 3-oxygenase (IDO) 1 is induced by pro-inflammatory




Fig. 3 The effect of a non-selective 5-HT₂ serotonergic receptor antagonist, cyproheptadine (CPH), a D₂, D₃, D₄ dopamine receptor antagonist, haloperidol (HPD) or a γ -aminobutyric acid subunit A receptor antagonist, bicuculline (BCL) in KYNA-induced antidepressant-like action in a modified mouse forced swim test. **1**, CPH pretreatment significantly increased immobility time and significantly decreased swimming time compared to KYNA. This suggests a possible involvement of the SER receptor in KYNA-induced antidepressant-like effects. Control ($N=15$), KYNA 2.0 mM *icv* ($N=15$), CPH 3.0 mg + KYNA 2.0 mM *icv* ($N=15$), CPH 3.0 mg/kg *ip* ($N=15$). **2**, HPD pretreatment did not change immobility and swimming times, but decreased climbing time compared to KYNA. This suggests

a minimal involvement of the D₂, D₃, D₄ DA receptor in KYNA-induced antidepressant-like effects. Control ($N=15$), KYNA 2.0 mM *icv* ($N=15$), HPD 10.0 μ g/kg *ip* + KYNA 2.0 mM *icv* ($N=14$), HPD 10.0 μ g/kg *ip* ($N=15$). **3**, BCL pretreatment increased immobility time, decreased climbing time and significantly decreased swimming time compared to KYNA. This suggests a possible involvement of the GABA_A receptor in KYNA-induced antidepressant-like effects. Control ($N=10$), KYNA 2.0 mM *icv* ($N=10$), BCL 2.0 mg/kg *ip* + KYNA 2.0 mM *icv* ($N=10$), BCL 2.0 mg/kg *ip* ($N=10$), x, $p < 0.05$ vs. control; +, $p < 0.05$ vs. KYNA, (N : the number of animals, p : probability)

cytokines such as α -interferon (IFN), γ -IFN, α -tumor necrosis factor, and so on [8, 9] (Fig. 1).

KYNA exhibited antidepressant-like effects by significantly decreasing immobility time, and significantly increasing climbing and swimming time in the modified FST in mice (Fig. 2). The *icv* administration of KYNA may overwhelm KYN, QUIN, and 3-HK actions at the NMDA receptors, resulting in the inhibition of the excitatory neuron pathway. The antidepressant-like effects of KYNA are reversed by the *ip* administration of SER antagonist, CPH. This suggests the possible involvement of SER receptors in the antidepressant-like effects of KYNA (Fig. 3; Table 1). It may also be assumed that the *icv* KYNA injection alters the KYN pathway balance, resulting in increased nicotinamide adenine dinucleotide (NAD⁺), which is responsible for the

feedback inhibition of TDO. Thus it facilitates the shunt of TRP metabolism from the KYN pathways toward the SER pathways to increase SER production [10].

The descending Glu-ergic neural pathway projects from the prefrontal cortex (PFC) toward the brain stem areas, innervating the substance nigra (SN), the ventral tegmental area (VTA), the midbrain raphe nuclei (MRN), and the locus coeruleus (LC). The VTA, MRN, and LC are the main brain areas where numerous serotonergic neurons originate [11, 12]. Thus, the inhibition of Glu-ergic neurotransmission may coordinate proper SER-ergic neuron firing, leading to antidepressant-like actions.

Anhedonia is one of the main symptoms of MDD and has been linked to dysfunction of the reward system in which DA neurotransmission plays a significant role. Animal models

Table 1 The involvement of receptors in KYNA-induced antidepressant-like action in modified combination mouse swim test

Receptors	Modified combination FST		
	Immobility	Climbing	Swimming
5-HT ₂ serotonin	High	Low	High
α-Adrenaline	–	–	–
α ₂ -Adrenaline	–	–	–
β-Adrenaline	–	–	–
D ₂ , D ₃ , D ₄ dopamine	–	Low	–
Muscarinic acetylcholine	–	–	–
N-methyl-D-aspartate	–	–	–
Gamma-aminobutyric acid subunit A	Low	Low	High

The antidepressant-like actions of KYNA strongly interacted with 5-HT₂ SER-ergic receptors, weakly interacted with D₂, D₃, D₄ DA-ergic receptors, and moderately interacted with GABA_A receptors. “–”: A receptor antagonist did not modify KYNA-induced antidepressant-like effects. “low”: A receptor antagonist modified KYNA-induced antidepressant-like effects with $p > 0.05$ vs. KYNA. “high”: A receptor antagonist modified KYNA-induced antidepressant-like effects with $p < 0.05$ vs. KYNA

of depression also demonstrate changes in the function for the mesolimbic DA system. Altered DA receptor expression within the limbic structures was observed in different models of depression, such as the learned helplessness model and the chronic mild stress model [13]. A D₂, D₃, D₄ DA receptor antagonist, HPD, influenced the climbing time in the modified combination FST. This suggests that the KYNA-induced antidepressant-like action may possibly be involved in DA receptor function (Fig. 3; Table 1).

Main DAergic neural pathways involved in MDD originate in the SN and VTA, which project toward the striatum, PFC and amygdala. Glu-ergic neurons from the PFC innervate the SN and VTA and may influence the DA-ergic neurotransmission. Furthermore, Glu-ergic neural pathways innervate the striatum and amygdala as part of the cortico-striatum–thalamus loop, and thus may influence DA-ergic neural effectors [11, 12].

In humans, about 80% of neurons in the neocortex are spiny and excitatory and form 85% of the synapses, indicating that Glu neurons and synapses occupy the largest part of the brain governed by a Glu-ergic excitatory neurons. It was reported that 2-amino-7-phosphonoheptanoic acid, a competitive NMDA subtype of Glu receptor antagonist, MK-801, a noncompetitive NMDA antagonist and 1-aminocyclopropanecarboxylic acid showed antidepressant-like effects in animal models [14]. Significantly higher cerebrospinal fluid (CSF) glutamine (Gln) concentrations were observed in MDD patients [15]. The findings are in accordance with antidepressant-like effects of KYNA as a NMDA receptor antagonist, which inhibits excitatory Glu-ergic neurotransmission.

Antidepressant-like effects induced by KYNA may be triggered by inhibition of the α7nAChR, leading to the reduction of Glu neurotransmitter, and by antagonistic inhibition of ionotropic AMPA, NMDA, and kainate subtypes of Glu receptors, present on presynaptic and postsynaptic neurons, as well as on glial cells, inhibiting rapid ionotropic effects. Noncompetitive NMDA receptor antagonist MK-801 did not affect KYNA-induced antidepressant-like action, showing that KYNA and MK-801 are not synergistic action at the NMDA receptors. A high dose of MK-801 is a potent antidepressant per se in FST. A lower dose was calibrated to study the modified FST in combination with its MK-801, but did not show any antidepressant effect in FST.

About 20% of the neurons are smooth and inhibitory and 15% of the synapses in the neocortex are occupied by GABA, which mediates fast inhibitory transmission. Deficits in GABA neurotransmission may contribute to MDD according to the findings of reduced GABA levels in plasma, CSF, and resected cortical tissue of MDD patients [15]. A significantly reduced behavioral reactivity in the open field and reduced glutamic acid decarboxylase mRNA expression in the limbic system were found in male rats on reboxetine, a NE reuptake inhibitor [16]. A significant increase in the occipital cortex GABA concentration was observed by proton magnetic resonance spectroscopy in MDD patients on fluoxetine, a selective SER reuptake inhibitor [17].

The GABA-ergic deficit hypothesis of depression suggests that the activation of the hypothalamus–pituitary–adrenal glands (HPA) axis is triggered by reduced GABA release in the hippocampus and frontal cortex, both of which are projecting to the paraventricular nucleus of the hypothalamus. That is, it is caused by reduced GABA-ergic synaptic inhibition in the HPA axis [18]. Other GABA-ergic neurons projecting toward the hypothalamus originate in NAc, where numerous neural pathways transit or destinate, including Glu-ergic neurons originating from the prefrontal cortex, amygdala, and hippocampus [11, 12]. Marked alterations in GABA_A receptor signaling are reported in both anxiety and mood disorders [19].

A GABA_A receptor antagonist, BCL, influenced the immobility and climbing times and prevented the effects of KYNA on swimming time in the modified mouse FST. It suggests KYNA triggered antidepressant-like actions through the GABA_A receptors (Fig. 3; Table 1). KYNA-induced antidepressant actions may be generated by shifting the Glu/GABA-Gln cycle in favor of more GABA production. Inhibitory GABA-ergic neurotransmission may be fine-tuned by a panel of neurotransmitters in the NAc; thus, it may help induce KYNA’s antidepressant-like actions. But, the involvement of KYNA inhibition at presynaptic α7nACh and the excitatory NMDA receptors triggering the

GABA-ergic neurotransmissions, and GABA production has yet to be investigated.

Meta-analysis of animal and human studies comparing metabolite levels of the KYN pathway between patients with depression and healthy controls showed that KYNA and KYN levels were slightly decreased in patients with MDD, ratios of KYNA/QUIN, as well as KYNA/3-HK, were lower in patients with depression, and there were no differences in QUIN and 3-HK levels between the two groups, presenting a strong evidence that the KYN pathway is involved in the pathophysiology of MDD [20].

Much evidence supports the involvement of KYN pathway products, KYNA, and NEKs in MDD. This work shows, for the first time, KYNA's antidepressant-like effects in a modified mouse FST. Furthermore, the antidepressant-like actions of KYNA interacted strongly with 5-HT₂ SER-ergic receptors, weakly with D₂, D₃, D₄ DA-ergic receptors, and in moderately with GABA_A receptors. KYNA's beneficiary antidepressant-like actions are to be explored further in the search for a potential novel therapeutic agent against MDD.

Acknowledgements Open access funding provided by University of Szeged (SZTE). This work was funded by GINOP 2.3.2-15-2016-00034, Ministry of Human Capacities, Hungary Grant 20391-3/2018/FEKUSTRAT and University of Szeged Open Access Fund (FundRef), Grant number 4639. We thank Ms. Jennifer Tusz, a native English speaker, for proofreading the manuscript.

Compliance with ethical standards

Conflict of interest There is no conflict of interest regarding this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Plangar I, Majlath Z, Vecsei L. Kynurenines in cognitive functions: their possible role in depression. *Neuropsychopharmacol Hung*. 2012;14(4):239–44.
- Vecsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: recent advances and new questions. *Nat Rev Drug Discov*. 2013;12(1):64–82.
- Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, et al. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. *Brain Behav Immun*. 2016;53:39–48.
- Pellegrino AS, Cushman AJ. *Stereotaxic atlas of the rat brain*. New York: Plenum Press; 1979.
- Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. *Pharmacol Biochem Behav*. 2000;67(1):137–43.
- Lapin IP. Kynurenines as probable participants of depression. *Pharmakopsychiatr Neuropsychopharmakol*. 1973;6(6):273–9.
- Vécsei L, Beal MF. Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. *Pharmacol Biochem Behav*. 1990;37(1):71–6.
- Oxenkrug GF. Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental Impacts in major depressive disorder: The serotonin hypothesis revisited 40 years later. *Isr J Psychiatry Relat Sci*. 2010;47:56–63.
- Mándi Y, Vécsei L. The kynurenine system and immunoregulation. *J Neural Transm (Vienna)*. 2012;119(2):197–209.
- Höglund E, Øverli Ø, Winberg S. Tryptophan Metabolic pathways and brain serotonergic activity: a comparative review. *Front Endocrinol (Lausanne)*. 2019;10:158.
- Palazidou E. The neurobiology of depression. *Br Med Bull*. 2012;101:127–45.
- Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. *Front Pharmacol*. 2012;3:195.
- Kram ML, Kramer GL, Ronan PJ, Steciuk M, Petty F. Dopamine receptors and learned helplessness in the rat: an autoradiographic study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2002;26:639–45.
- Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. *Eur J Pharmacol*. 1990;185:1–10.
- Honig A, Bartlett JR, Bouras N, Bridges PK. Amino acid levels in depression: a preliminary investigation. *J Psychiatr Res*. 1988;22:159–64.
- Herman JP, Renda A, Bodie B. Norepinephrine-gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. *Biol Psychiatry*. 2003;53:166–74.
- Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. *Am J Psychiatry*. 2002;159:663–5.
- Luscher B, Shen Q, Sahir N. The GABAergic Deficit hypothesis of major depressive disorder. *Mol Psychiatry*. 2011;16(4):383–406.
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. *Nat Neurosci*. 2000;3:587–92.
- Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2018;90:16–25.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.